一般演題１５

[O15-1] 中等症から重症のクローン病患者に対するグセルクマブの有効性と安全性:GALAXI 2&3寛解維持試験

*久松 理一¹、Remo Panaccione²、Silvio Danese³、Brian Feagan⁴、Geert D’Haens⁵、Anita Afzali⁶、Walter Reinisch⁷、Julián Panés⁸、David T. Rubin⁹、Jane Andrews¹⁰、Natalie A Terry¹¹、Leonardo Salese¹¹、Rian Van Rampelbergh¹¹、Mary Ellen Frustaci¹¹、Zijiang Yang¹¹、Jewel Johanns¹¹、Kitty Yuen Yi Wan¹¹、Jacqueline Yee¹¹、坂本 武彦¹²、 吉越 真一¹²、佐々木 絢子¹²、Bruce E. Sands¹³ (1. 杏林大学医学部消化器内科学、2. University of Calgary、3. IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University、4. Alimentiv Inc、5. Amsterdam University Medical Centers、6. University of Cincinnati College of Medicine、7. Medical University of Vienna、8. Hospital Clínic de Barcelona, IDIBAPS, CIBERehd、9. University of Chicago School of Medicine Inflammatory Bowel Disease Center、10. Gastrointestinal Services, Surgery Program, Central Adelaide Local Health Network and University of Adelaide、11. Janssen Research & Development、12. ヤンセンファーマ株式会社、13. Icahn School of Medicine at Mount Sinai)